STOCK TITAN

Organigram Global (OGI) Stock Price, News & Analysis

OGI NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
29 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
+17.1% close of August 11, 2026
1-year change
-56.3% closing prices, November 18, 2025 to November 18, 2026
1-month change
-27% closing prices, October 16, 2026 to November 18, 2026

Company Description

Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) is a cannabis company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator and manufacturer of cannabis and cannabis-derived goods in Canada. The company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations and operates in the medicinal and botanical manufacturing industry within the broader manufacturing sector. Organigram focuses on producing high-quality cannabis for adult consumers and participates in both recreational and medical markets, as well as cannabinoid beverage and hemp-derived THC categories.

According to multiple company disclosures, Organigram describes itself as Canada’s number one cannabis company by market share in the recreational segment. It has developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, DEBUNK and Collective Project. These brands span categories such as dried flower, pre-rolls, vapes, concentrates, edibles and beverages as described in the company’s news releases.

Operations and Facilities

Organigram operates cultivation and processing facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec. It also runs a dedicated edibles manufacturing facility in Winnipeg, Manitoba. In Southwestern Ontario, the company operates two additional cannabis processing facilities in Aylmer and London. The Aylmer facility houses CO2 and hydrocarbon extraction capabilities and is described as optimized for formulation refinement, post-processing of minor cannabinoids and infused or pre-roll production. The London facility is being optimized for labelling, packaging and national fulfillment, supporting Organigram’s distribution across Canada.

Through its acquisition of Collective Project Limited, Organigram participates in the U.S. and Canadian cannabinoid beverages markets. The company has also entered the U.S. hemp-derived THC space with products such as Collective Project sparkling juices, Fetch sodas and the happly brand, as outlined in its news announcements. These initiatives extend Organigram’s reach beyond traditional inhalable formats into beverages and ingestible products.

Brands and Product Focus

Organigram’s brand portfolio is a central element of its strategy. The company highlights brands such as Edison, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Tremblant, Trailblazer, BOXHOT, DEBUNK, Holy Mountain and Collective Project in its public communications. Within the Canadian recreational market, Organigram reports leadership positions in categories including vapes, pre-rolls, milled flower and concentrates, and meaningful presence in edibles and dried flower. Product launches referenced in company news include SHRED Max10 Party Pack gummies, Big Bag O’ Buds strains, SHRED Flower Power blends, BOXHOT infused pre-rolls, Trailblazer blunts and Rizzlers vapes.

In the U.S. hemp-derived THC market, Organigram has introduced happly, a brand of hemp-derived delta-9 THC gummies formulated around mood states such as socialize, relax and sleep. The company notes that happly uses its FAST™ nanoemulsion technology to support a more consistent and predictable onset and offset of effects. Organigram positions happly for consumers seeking moderation, control and predictability in their cannabis experiences, based on its internal market segmentation work.

Innovation, Genetics and Cultivation

Organigram emphasizes innovation in cultivation and product development. The company has invested in seed-based cultivation and cannabis genetics through its relationship with Phylos Bioscience Inc. Organigram states that seed-based cultivation has become a key advantage in its cultivation strategy, contributing to consistency, scalability and economic benefits. Through an expanded agreement with Phylos, Organigram has secured access to an autoflower genetics pipeline and a long-term seed supply, with exclusivity for chosen cultivars in certain international markets such as Canada, Australia, the UK, Germany and Israel for specified periods.

The company also reports genomics research and development, including work to identify genetic markers for powdery mildew resistance and breeding that resistance into key cultivars. Organigram links these efforts to goals such as reducing plant care requirements and increasing yields. It has reported record harvests at its Moncton facility, attributing them to enhanced cultivation practices, upgraded lighting and seed-based cultivation.

International and Beverage Expansion

Organigram has an international business unit focused on exporting cannabis products and building partnerships in high-value medical and adult-use markets. The company discloses record international sales and ongoing work toward EU-GMP certification for its Moncton facility, which is a prerequisite for certain international medical cannabis markets. It has also highlighted five-year exclusive rights for selected cannabis genetics in specified international territories under its amended agreement with Phylos, with the ability to add new territories as its global expansion continues.

In beverages, Organigram participates in cannabinoid drinks in both Canada and the U.S. through Collective Project and related brands. The company notes expanded Canadian beverage distribution in provinces such as Alberta, Saskatchewan and Manitoba, and U.S. direct-to-consumer availability of hemp-derived THC beverages in multiple states. These activities are part of its stated goal to extend its global footprint and diversify product formats.

Financial Reporting and Public Listings

Organigram Global Inc. is listed on the NASDAQ Global Select Market and the Toronto Stock Exchange under the symbol OGI. As a foreign private issuer, it files reports with the U.S. Securities and Exchange Commission on Form 6-K and Form 40-F, and it also files continuous disclosure documents on SEDAR+ in Canada. The company reports non-IFRS measures such as adjusted gross margin, adjusted gross margin percentage, adjusted EBITDA and free cash flow in its financial news releases, explaining that these metrics are used by management to assess financial and operational performance.

Recent financial updates referenced in company news include record quarterly and annual revenues, growth in adjusted EBITDA, and increased international sales. Organigram also discusses the impact of acquisitions such as Motif Labs Ltd. and Collective Project Limited on its revenue, extraction capabilities and beverage presence. It reports on cost efficiencies, synergy realization and changes in gross margin, while noting that non-IFRS measures do not have standardized meanings under IFRS.

Corporate Strategy and Industry Role

Organigram positions itself as a Canadian cannabis producer with ambitions to compete globally. The company highlights a strategy built around brand development, cultivation and extraction capabilities, product innovation, international expansion and participation in adjacent categories such as beverages and hemp-derived THC. It has partnered with organizations such as the Canadian Chamber of Commerce’s Business Data Lab to analyze the economic footprint of Canada’s legal cannabis industry, and has released reports describing cannabis as a significant contributor to national GDP, economic output and employment.

In its public communications, Organigram advocates for policy modernization in areas such as excise taxation and export strategies, arguing that the legal cannabis sector represents an important part of the Canadian economy. The company’s polling work with Abacus Data indicates that a majority of surveyed Canadians see the legal cannabis industry as an economic opportunity and support greater government involvement in fostering jobs and innovation in the sector.

Regulatory Environment

Organigram operates under the Cannabis Act and the Cannabis Regulations in Canada, and references Health Canada as its primary regulator for cultivation and processing activities. For its U.S. hemp-derived THC activities, the company’s disclosures focus on product launches and distribution rather than detailed regulatory frameworks, but they consistently distinguish these products as hemp-derived and note that they are offered in states where such products can be sold.

Stock Performance

$0.6627
-2.05%
-0.0139
After hoursChange vs the $0.6766 closeLast updated: at
-56.3%
Performance 1 year
$93.5M

Organigram Global (OGI) closed at $0.6766 on November 18, 2026. Over the past 12 months, the price has lost 56.3%.

See what a $1,000 investment in OGI would be worth today

Average down calculator for OGI

OGI Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Organigram Global has 10 recent news articles, with the latest published on . Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include acquisition, earnings date. View all OGI news →

Financial Highlights

Organigram Global generated $186.1M in revenue in FY2025, retaining a 34.8% gross margin, operating income reached -$11.0M (-5.9% operating margin), and net income was -$17.8M, reflecting a -9.6% net profit margin. Diluted earnings per share stood at -$0.14. The company generated -$5.5M in operating cash flow. The current ratio was 2.26, measuring current assets divided by current liabilities.

$186.1M
Revenue (FY2025)
-$17.8M
Net Income (FY2025)
-$5.5M
Operating Cash Flow

Upcoming Events

JAN
2027
January 2027 Corporate

Acquisition closing

Expected transaction closing in Jan 2027, subject to shareholder, regulatory and Supreme Court of British Columbia approvals.
APR
01
April 1, 2027 - March 31, 2028 Financial

Full annualized benefit

Organigram expects to realize the full $8M–$10M annualized run-rate savings in fiscal 2028 following integration completion.
APR
01
April 1, 2027 - May 1, 2027 Financial

Earnout payment

Fixed earnout payment of €20M cash and ~€76M in Organigram shares; TSX VWAP C$3.00–C$4.00 collar; payable Apr 1–May 1, 2027.
MAY
10
May 10, 2027 Regulatory

Nasdaq compliance deadline

Nasdaq notice: deadline May 10, 2027 to regain $1.00 closing bid for 10 consecutive business days to avoid delisting.
MAY
25
May 25, 2028 Financial

Loan maturity

US$10M loan matures; subject to conversion or other resolution mechanisms

Organigram Global has 5 upcoming scheduled events. The next event, "Acquisition closing", is expected in January 2027. 3 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the OGI stock price.

Short Interest History

Last 12 Months

Short interest in Organigram Global (OGI) currently stands at 5.3 million shares, up 10.3% from the previous reporting period, representing 5.5% of the float.

Days to Cover History

Last 12 Months

Days to cover for Organigram Global (OGI) currently stands at 21.2 days, up 82.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 128.5%. Across the settlements charted above, it has ranged from 1.4 to 22.1 days.

OGI Company Profile & Sector Positioning

Organigram Global (OGI) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing OGI often look at related companies in the same sector, including Journey Medical Corporation (DERM), Cardiol Therapeutics Inc. (CRDL), BGM Group Ltd. (BGM), Akebia Therapeutics, Inc. (AKBA), and Organogenesis Holdings Inc. (ORGO). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate OGI's relative position within its industry.

Frequently Asked Questions

The current stock price of Organigram Global (OGI) is $0.6627 in after-hours trading as of November 18, 2026.

The market cap of Organigram Global (OGI) is approximately $93.5M. Learn more about what market capitalization means .

The FY2025 revenue of Organigram Global (OGI) is $186.1M, from its most recent completed fiscal year.

The FY2025 net income of Organigram Global (OGI) is -$17.8M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Organigram Global (OGI) is -$0.14 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Organigram Global (OGI) is -$5.5M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Organigram Global (OGI) is -9.6% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Organigram Global (OGI) is -5.9% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Organigram Global (OGI) is 34.8% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Organigram Global (OGI), current assets divided by current liabilities, was 2.26 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Organigram Global (OGI) is $64.8M for FY2025, its most recent completed fiscal year.

The operating income of Organigram Global (OGI) is -$11.0M for FY2025, its most recent completed fiscal year. Learn about operating income.

Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator and manufacturer of cannabis and cannabis-derived goods in Canada. The company focuses on producing high-quality cannabis for adult consumers and participates in both recreational and medical markets, as well as cannabinoid beverage and hemp-derived THC categories, according to its public news releases.

Organigram operates cultivation and processing facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec. It has a dedicated edibles manufacturing facility in Winnipeg, Manitoba, and two cannabis processing facilities in Southwestern Ontario, located in Aylmer and London. The Aylmer site focuses on extraction, formulation refinement, post-processing of minor cannabinoids and pre-roll production, while the London facility is being optimized for labelling, packaging and national fulfillment, as described in company announcements.

Organigram reports that it has developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, DEBUNK and Collective Project. These brands are mentioned across multiple company news releases as part of its Canadian and international product offerings.

Through its acquisition of Collective Project Limited, Organigram participates in the U.S. and Canadian cannabinoid beverages markets. The company notes expanded Canadian beverage distribution in provinces such as Alberta, Saskatchewan and Manitoba, and reports U.S. direct-to-consumer availability of hemp-derived THC beverages in multiple states, according to its financial and product launch news releases.

Organigram has entered the U.S. hemp-derived THC market with products such as Collective Project sparkling juices, Fetch sodas and the happly brand. The company describes happly as a hemp-derived delta-9 THC brand offering gummies formulated around mood states like socialize, relax and sleep, and notes that these products use its FAST™ nanoemulsion technology. Details are provided in the company’s happly launch press release.

In several news releases, Organigram refers to itself as Canada’s number one cannabis company by market share in the recreational segment, and Canada’s number one recreational cannabis company by market share. It also highlights leadership positions in specific categories such as vapes, pre-rolls, milled flower and concentrates, and strong rankings in edibles and dried flower, based on cited market share data in its financial updates.

Organigram has invested in cannabis genetics and seed-based cultivation through its relationship with Phylos Bioscience Inc. The company states that seed-based cultivation has become a key advantage in its cultivation strategy, supporting consistency, scalability and economic benefits. An expanded agreement with Phylos provides access to an autoflower genetics pipeline and long-term seed supply, with exclusivity for selected cultivars in specified international markets, as described in its December 31, 2025 news release.

Organigram reports record international sales and states that it is developing international business partnerships to extend its global footprint. It references work toward EU-GMP certification for its Moncton facility, international exports, and exclusive rights for certain cannabis genetics in markets such as Canada, Australia, the UK, Germany and Israel. These points appear in its financial results and Phylos agreement news releases.

Organigram Global Inc. is listed on the NASDAQ Global Select Market and the Toronto Stock Exchange, both under the symbol OGI. This listing information is repeated in multiple company news releases and in its Form 6-K filings with the U.S. Securities and Exchange Commission.

Organigram provides financial updates through press releases and Form 6-K filings, including condensed consolidated interim financial statements and management’s discussion and analysis. It reports IFRS figures and also uses non-IFRS measures such as adjusted gross margin, adjusted gross margin percentage, adjusted EBITDA and free cash flow, explaining that these metrics are used by management to assess financial and operational performance, as detailed in its quarterly and annual results announcements.